AMIT PATEL: Open Payments
NPI 1396409884 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,384 in 51 payments from 18 companies in 2025. Trend: 2023 $1,496 · 2024 $938 · 2025 $1,384
Food & beverage: $1,304Education: $80
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $290 |
| Galderma Laboratories, L.P. | 7 | $177 |
| Regeneron Healthcare Solutions, Inc. | 1 | $137 |
| E.R. Squibb & Sons, L.L.C. | 2 | $97 |
| Lilly USA, LLC | 4 | $89 |
| LEO Pharma Inc. | 3 | $86 |
| Organon LLC | 2 | $83 |
| GENZYME CORPORATION | 2 | $79 |
| Incyte Corporation | 3 | $75 |
| Novartis Pharmaceuticals Corporation | 4 | $68 |
Products named: DUPIXENT, SKYRIZI, NEMLUVIO, RINVOQ, Sotyktu, VTAMA, OPZELURA, COSENTYX.
Industry payments across CA — which companies pay providers there.
